ROS1陽性非小細胞肺癌:ゲノミクスから治療決定まで

Mylène Wespiser¹, Romane Gille¹, Maurice Pérol¹

¹Department of Medical Oncology, Centre Léon Bérard, Lyon, France.

Frontiers in oncology

|February 18, 2026

まとめ

非小細胞肺がん (NSCLC) のROS1の再編成は標的となる. 次世代のTKIは治療結果を改善しますが,耐性については,個別化された治療と持続的な治療のために分子再評価が必要になります.

科学分野:

腫瘍学腫瘍学
遺伝学遺伝学とは
薬理学薬理学とは

背景:

ROS1の再編成は,非小細胞肺がん (NSCLC) のターゲットとなるサブセット (~2%) を特定します.
これらの再編成は,しばしば転移性疾患と中枢神経系 (CNS) の関与を伴います.
既存のROS1チロシンキナーゼ阻害剤 (TKIs) は結果を改善しますが,避けられない抵抗に直面します.

研究の目的:

ROS1の生物学,診断,治療,およびNSCLCにおける耐性メカニズムに関する現在の知識をレビューする.
ROS1 リアレンジされたNSCLCの管理のための実践指向の枠組みを提供すること.
ターゲティングセラピーの進歩と将来の研究優先事項を強調する.

主な方法:

NSCLCにおけるROS1の再編成に関する現在の文献のまとめ.
ROS1の融合アーキテクチャ,シグナリング,パートナー特有の特徴の概要.
RNAベースの次世代シーケンシング (NGS) に焦点を当てた診断方法の要約.

主要な成果:

RNAベースのNGSは,融合検出と抵抗プロファイルの最も敏感な方法である.
中枢神経系に浸透する次世代のTKIは,抵抗性変異に対して有効性を示す,好ましい第一線療法です.
レポトレクチニブ,タレトレクチニブ,ジデサミチニブは,有意な全身および頭蓋内活性を示しています.

結論:

シーケンシング戦略の最適化,外科手術後のアプローチの評価,ゲノムモニタリングの最適化は,重要な優先事項です.
進歩により,ROS1再編成型NSCLCの自然史が,精度駆動型パラダイムへ向けて改善されています.
進行時の分子再評価は,その後の量身治療の指針を定める上で極めて重要です.

キーワード:

ROS1の再編成クリニック・トライアル臨床試験薬剤耐性薬剤耐性薬剤耐性とは非小細胞肺がんは,小細胞でない肺がんである.オンコゲン中毒者とはタイロシンキナーゼ阻害剤タイロシンキナーゼ阻害剤

さらに関連する動画

05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

442

10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.8K

関連する概念動画

02:56

Treatment Resistant Cancers

3.8K

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

3.8K

02:57

Targeted Cancer Therapies

9.0K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

9.0K

01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

02:50

Combination Therapies and Personalized Medicine

6.2K

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

6.2K

01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

関連する実験動画